By otakuyassine3@gmail.com 
Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CFO Eva Renee Barnett sold 2,298 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total transaction of $54,761.34. Following the sale, the chief financial officer now owns 324,766 shares of the company’s stock, valued at approximately $7,739,173.78. The trade was a 0.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Eva Renee Barnett also recently made the following trade(s):
- On Wednesday, January 8th, Eva Renee Barnett sold 4,105 shares of Immunovant stock. The shares were sold at an average price of $24.10, for a total value of $98,930.50.
- On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The shares were sold at an average price of $25.45, for a total value of $106,228.30.
- On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The stock was sold at an average price of $25.45, for a total value of $106,228.30.
Immunovant Stock Up 0.3 %
Shares of IMVT stock traded up $0.06 on Friday, reaching $23.86. The company’s stock had a trading volume of 1,032,612 shares, compared to its average volume of 1,051,056. Immunovant, Inc. has a 12-month low of $22.41 and a 12-month high of $41.38. The company has a market capitalization of $3.50 billion, a P/E ratio of -10.75 and a beta of 0.66. The stock’s 50 day simple moving average is $26.53 and its 200-day simple moving average is $28.50.
Immunovant (NASDAQ:IMVT – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same period in the prior year, the firm posted ($0.45) EPS. Research analysts expect that Immunovant, Inc. will post -2.75 EPS for the current year.
Hedge Funds Weigh In On Immunovant
Several institutional investors have recently modified their holdings of IMVT. Principal Financial Group Inc. lifted its position in Immunovant by 69.9% in the 3rd quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock worth $27,117,000 after buying an additional 391,436 shares during the last quarter. Tyro Capital Management LLC raised its position in Immunovant by 0.6% in the 3rd quarter. Tyro Capital Management LLC now owns 252,149 shares of the company’s stock worth $7,189,000 after purchasing an additional 1,529 shares during the period. Geode Capital Management LLC lifted its stake in Immunovant by 6.9% in the third quarter. Geode Capital Management LLC now owns 1,510,926 shares of the company’s stock worth $43,085,000 after purchasing an additional 96,924 shares during the last quarter. State Street Corp boosted its position in Immunovant by 11.2% during the third quarter. State Street Corp now owns 3,022,342 shares of the company’s stock valued at $86,167,000 after buying an additional 303,386 shares during the period. Finally, Baker BROS. Advisors LP grew its stake in shares of Immunovant by 163.7% during the third quarter. Baker BROS. Advisors LP now owns 1,225,410 shares of the company’s stock valued at $34,936,000 after buying an additional 760,692 shares during the last quarter. 47.08% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
IMVT has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Immunovant in a research note on Friday, November 8th. Bank of America lowered their price target on shares of Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday. Wolfe Research downgraded shares of Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. Wells Fargo & Company lowered their target price on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, Oppenheimer raised their price target on Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.00.
View Our Latest Report on IMVT
About Immunovant
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Further Reading
Receive News & Ratings for Immunovant Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Immunovant and related companies with MarketBeat.com’s FREE daily email newsletter.